A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL

被引：0
|
作者：
Gehlert, C. L. [1 ]
Schewe, D. M. [2 ]
Klausz, K. [1 ]
Schrappe, M. [1 ]
Cario, G. [1 ]
Baldus, C. D. [1 ]
Gramatzki, M. [1 ]
Lenk, L. [1 ]
Kellner, C. [2 ]
Peipp, M. [1 ]
机构：
[1] Univ Hosp Schleswig Holstein, Kiel, Germany
[2] Otto von Guericke Univ, Magdeburg, Germany
来源：
KLINISCHE PADIATRIE | 2024年 / 236卷 / 03期
关键词：
D O I：
10.1055/s-0044-1786578
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
0027
引用
收藏
页码：205 / 205
页数：1
相关论文
共 50 条
  • [21] IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS
    Kovtun, Y.
    Jones, G.
    Harvey, L.
    Rui, L.
    Audette, C.
    Liu, F.
    Bai, C.
    Wilhelm, A.
    Yoder, N. C.
    Adams, S.
    Goldmacher, V. S.
    Chari, R.
    Chittenden, T.
    HAEMATOLOGICA, 2016, 101 : 222 - 222
  • [22] Bispecific antibody drug conjugates targeting CD7 and CD33 for the treatment of acute myeloid leukemia
    Bethell, Richard
    Eberlein, Cath
    Pollard, Victoria
    Georgiou, Theonie
    Orphanides, George
    Mooney, Lorraine
    Kendrew, Jane
    Daniels, Tiffany
    CANCER RESEARCH, 2020, 80 (16)
  • [23] Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
    Sun, Zehua
    Chu, Xiaojie
    Adams, Cynthia
    V. Ilina, Tatiana
    Guerrero, Michel
    Lin, Guowu
    Chen, Chuan
    Jelev, Dontcho
    Ishima, Rieko
    Li, Wei
    Mellors, John W.
    Calero, Guillermo
    Dimitrov, Dimiter S.
    MOLECULAR THERAPY ONCOLYTICS, 2023, 31
  • [24] Targeting B7-H3 (CD276) in neuroblastoma: In vitro evaluation of Fc-optimized antibodies and immunocytokines
    Heubach, Florian
    Schlegel, Patrick
    Zekri, Latifa
    Manz, Timo
    Schleicher, Sabine
    Rabsteyn, Armin
    Jung, Gundram
    Buehring, Hans-Joerg
    Gillies, Stephen D.
    Handgretinger, Rupert
    Lang, Peter
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [25] SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
    Sutherland, May S. Kung
    Walter, Roland B.
    Jeffrey, Scott C.
    Burke, Patrick J.
    Yu, Changpu
    Kostner, Heather
    Stone, Ivan
    Ryan, Maureen C.
    Sussman, Django
    Lyon, Robert P.
    Zeng, Weiping
    Harrington, Kimberly H.
    Klussman, Kerry
    Westendorf, Lori
    Meyer, David
    Bernstein, Irwin D.
    Senter, Peter D.
    Benjamin, Dennis R.
    Drachman, Jonathan G.
    McEarchern, Julie A.
    BLOOD, 2013, 122 (08) : 1455 - 1463
  • [26] From bench to bedside: Reduction of minimal residual disease in children with ALL by a newly developed, Fc-optimized CD19 antibody
    Seidel, U. J. E.
    Grosse-Hovest, L.
    Schlegel, P.
    Hofmann, M.
    Schuster, F. R.
    Meisel, R.
    Witte, K-E
    Aulwurm, S.
    Teltschik, R.
    Pyz, E.
    Rammensee, H-G
    Jung, G.
    Handgretinger, R.
    Lang, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 114 - 114
  • [27] Preclinical evaluation of a novel MET antibody-drug conjugate in uveal melanoma models
    Surriga, Oliver
    DaSilva, John
    Schwartz, Gary K.
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Intracellular retention of TCRαβ/CD3 and CD7 to generate novel allogeneic CAR-T cells targeting CD7 for treating T-cell malignancies
    Li, Jun
    Liu, Kaichun
    Fu, Jianmin
    Chen, Shanshan
    Zhang, Yinhang
    Xu, Guanggui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
    Mueller, Kristina
    Vogiatzi, Fotini
    Winterberg, Dorothee
    Rosner, Thies
    Lenk, Lennart
    Bastian, Lorenz
    Gehlert, Carina L.
    Autenrieb, Marie-Pauline
    Bruggemann, Monika
    Cario, Gunnar
    Schrappe, Martin
    Kulozik, Andreas E.
    Eckert, Cornelia
    Bergmann, Anke K.
    Bornhauser, Beat
    Bourquin, Jean-Pierre
    Valerius, Thomas
    Peipp, Matthias
    Kellner, Christian
    Schewe, Denis M.
    BLOOD, 2022, 140 (01) : 45 - 57
  • [30] ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
    Smith, Roger A.
    Zammit, David J.
    Damle, Nitin K.
    Usansky, Helen
    Reddy, Sanjeeva P.
    Lin, Jun-Hsiang
    Mistry, Mahesh
    Rao, Niranjan S.
    Denis, Louis J.
    Gupta, Sandeep
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1327 - 1337
12345